http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck's (MRK) LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone Recommended for Approval in EU
-
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prost
-
Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)
-
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
-
Veeva Systems (VEEV) and Merck (MRK) Enter Long-Term Strategic Partnership
-
Veeva and Merck Form Long-Term Strategic Partnership
-
Merck Announces Third-Quarter 2022 Financial Results
-
Merck (MRK) Announces Robert M. Davis to Succeed Kenneth C. Frazier as Chairman
-
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
-
Merck (MRK) Granted Expanded EU VAXNEUVANCE Indication to Include Infants, Children and Adolescents
-
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
-
Merck (MRK) Reports Positive Phase 3 Data of PREVYMIS for Prevention of Cytomegalovirus Disease
-
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
-
Merck Animal Health Launches Sure Petcare Animo® GPS
-
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
-
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
-
Merck (MRK) Reports Positive Top-line Results from Pivotal Phase 3 STELLAR Trial of Sotatercept
-
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
-
Merck (MRK) and Ridgeback Biotherapeutics Provide Update on New Studies of LAGEVRIO
-
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
-
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
-
Merck (MRK) Announces U.S. Court of Appeals for Federal Circuit Rules in Favor of it in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
-
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
-
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
-
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
-
Merck (MRK) KEYTRUDA Granted Four New Approvals in Japan
-
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
-
Merck Animal Health (MRK) to Acquire Vence
-
Merck Animal Health to Acquire Vence
-
Merck (MRK) Announces Court Ruling in Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
-
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
-
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
-
Merck (MRK) to Initiate New Phase 3 Trial with Lower Dose of Daily Oral Islatravir with Doravirine for Treatment of People with HIV-1 Infection
-
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
-
Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
-
Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
-
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
-
Seagen (SGEN), Merck (MRK) and Astellas Report Results of Trial Investigating PADCEV
-
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
-
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
-
Merck (MRK) Announces Strong Five-Year Data for KEYTRUDA Plus Chemotherapy in NSCLC
-
Merck (MRK) and Eisai Report Results From Phase 3 LEAP-002 Trial of KEYTRUDA Plus LENVIMA
-
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Ca
-
Merck (MRK) Announces LYNPARZA in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in
-
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Explorat
-
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
-
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
Merck Reports Strong Progress in ESG Focus Areas
-
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
